盐酸齐拉西酮与帕罗西汀治疗精神分裂症伴抑郁症患者的临床效果分析

Clinical effect of ziprasidone hydrochloride and Paroxetine in treatment of schizophrenia with depression

目的研究和探讨盐酸齐拉西酮与帕罗西汀治疗精神分裂症伴抑郁症患者的临床效果分析。方法本次所研究的精神分裂症伴抑郁症患者均选自2016年10月至17年12月期间在洛阳市精神卫生中心就诊的该类患者,随机分为(盐酸齐拉西酮治疗组)观察组和(帕罗西汀治疗组)对照组。对两组患者治疗前及治疗后2、4、8周的PANSS及CDSS评分进行比较分析,同时两组患者治疗后的不良反应发生情况进行比较,且对两组患者治疗前及治疗8周后的执行功能进行比较。结果 PANSS及CDSS评分量表结果显示,两组患者在治疗前比较无差异,且执行功能无差异,无统计学意义(P> 0. 05);治疗后,结果显示2、4周PANSS及CDSS评分,观察组优于对照组,组间比有差异(P <0. 05);但8周后,两组PANSS及CDSS评分结果显示,两组比较无差异(P> 0. 05);但在执行功能方面,观察组更优于对照组,组间比有差异(P <0. 05);治疗后,观察组出现恶心、锥体外系反应以及焦虑等不良反应的发生率(39. 21%),明显少于对照组的(60. 78%),组间比有差异(P <0. 05)。结论盐酸齐拉西酮与帕罗西汀均能较好治疗精神分裂症,但盐酸齐拉西酮起效更快更明显,且在治疗抑郁症方面,盐酸齐拉西酮明显优于帕罗西汀,且不良反应较少,值得临床上推广应用。

Objective To study and explore the clinical effect of Ziprasidone hydrochloride and Paroxetine in the treatment of schizophrenic patients with depression. Methods The schizophrenics and depressive patients studied in this study were selected from October 2016 to September 17 in our hospital. They were randomly divided into the observation group（ ziprasidone hydrochloride group） and the control group（ Paroxetine treatment group）. The PANSS and CDSS scores of the two groups before treatment and 2,4 and 8 weeks after treatment were compared and analyzed. Meanwhile,the occurrence of adverse reactions after treatment in two groups were compared,and the executive function of two groups before treatment and after 8 weeks treatment were compared. Results PANSS and CDSS scores showed that two groups of patients before treatment had no significant difference between executive function,and no difference,no statistical significance（ P〉0. 05）; After treatment,the results showed that 2 and 4 weeks PANSS and CDSS scores,the observation group than the control group,there are differences between groups than（ P〈0. 05）,but after 8 weeks,two groups of PANSS and CDSS scores showed that two groups have no difference（ P〉0. 05）,but in executive function,the observation group was better than the control group,there were differences between groups than（ P〈0. 05）; After treatment,the incidence of adverse reaction in the observation group of nausea, extrapyramidal the reaction and anxiety（ 39. 21%）,significantly less than the control group（ 60. 78%）,between the groups was significant difference（ P〈0. 05）. Conclusion Ziprasidone hydrochloride and Paroxetine both can treat schizophrenia better,but ziprasidone hydrochloride has faster and more obvious effect. In the treatment of depression,ziprasidone hydrochloride is obviously better than Paroxetine,and has fewer side effects,so it is worthy of clinical application.